-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Clover Biology was listed on the Hong Kong Stock Exchange
.
It is worth noting that the issue price fell below the issue price on the first day of listing, closing at HK$12.
98, a drop of 2.
99% from the issue price of HK$13.
38
.
In the next few days, the share price of Clover Biology continued to fall, with a decline of as high as 30%.
As of the close of the 11th, it was reported at 9.
17 Hong Kong dollars, with a total market value of 10.
62 billion Hong Kong dollars
.
In addition to Shamrock Bio, on November 11, Hualan shares also performed poorly on the first day of listing on the Shenzhen Stock Exchange’s ChiNext, directly falling below the issue price
.
It is understood that, in fact, the break of the pharmaceutical stocks has long been foretelling
.
Since September, pharmaceutical stocks have set off a wave of breaks
.
In the third quarter of this year alone, among the Hong Kong pharmaceutical stocks, four of the seven unprofitable new biopharmaceutical stocks were all in a break state, including Xinwei Medical, Chuangsheng Group, Kunbo Medical, and Advanced Medical
.
Among them, Xinwei Medical, sponsored by Goldman Sachs CICC, whose share price has been slashed since its listing
.
In addition, among the A-shares, the first day performance of Chengda Biotech, which was listed on October 28, was also surprising
.
As of the close of trading, the stock price has fallen by 27.
27%
.
In addition, according to incomplete statistics, after September this year, A shares also ushered in a wave of breaks
.
First, the listing applications of the two biomedical companies, Haihe Pharmaceutical and Jikai Gene, were rejected by the Securities Regulatory Commission before and after the listing, and then the number of companies accepted for listing on the Science and Technology Innovation Board has also changed significantly
.
Among them, the number of companies that accepted the Sci-tech Innovation Board in September was 13; in October, only 4 companies were accepted on the Sci-Tech Innovation Board, and there were no biomedical companies
.
The analysis believes that there are many reasons for the wave of break-ups, including the accelerated pace of new stock issuance, the recent lack of market sentiment, and the continuous high-priced issuance caused by the blind praise of "unbeaten new stocks" by all parties in the market
.
But in general, this type of break is not a bad thing.
The mature capital market itself has risen and fallen.
New stocks are the same as old stocks.
They should not necessarily go up just because they are new stocks.
.
At present, as the issuance of pharmaceutical stocks continues to break, the industry is expected to promote the rational return of new stock returns, and change IPO pricing from a game of behavior to a judgment on the true value of new stocks
.
It is worth mentioning that behind the successive breaks of the pharmaceutical stocks, some people in the industry have also pointed out that research capabilities are gradually replacing the finalist rate as the new distribution logic
.
Because on the whole, most of the products of companies that have fallen below the issue price have no real innovation
.
For example, the recently launched medical device companies such as Weitai Medical, Synred Medical, and Guichuang Tongqiao, whose main products are still around products such as embolization stents, drug balloons, insulin pumps, and interventional diagnosis and treatment
.
Although these products may have innovative technical points, there is no fundamental breakthrough in the treatment essence of products that have been circulating on the market for many years
.
What's more, these products are likely to face national centralized procurement in the future
.
In this context, the industry pointed out that as the market matures, future innovative drug companies are expected to be polarized after they go public: companies with innovative capabilities, R&D capabilities, and excellent products will be sought after by investors, and their stock prices will continue to rise; on the contrary, Companies with no innovation, backward R&D capabilities, and no distinctive features may experience issuance failure, breakage, low transaction volume (market value), or even delisting
.
.
It is worth noting that the issue price fell below the issue price on the first day of listing, closing at HK$12.
98, a drop of 2.
99% from the issue price of HK$13.
38
.
In the next few days, the share price of Clover Biology continued to fall, with a decline of as high as 30%.
As of the close of the 11th, it was reported at 9.
17 Hong Kong dollars, with a total market value of 10.
62 billion Hong Kong dollars
.
In addition to Shamrock Bio, on November 11, Hualan shares also performed poorly on the first day of listing on the Shenzhen Stock Exchange’s ChiNext, directly falling below the issue price
.
It is understood that, in fact, the break of the pharmaceutical stocks has long been foretelling
.
Since September, pharmaceutical stocks have set off a wave of breaks
.
In the third quarter of this year alone, among the Hong Kong pharmaceutical stocks, four of the seven unprofitable new biopharmaceutical stocks were all in a break state, including Xinwei Medical, Chuangsheng Group, Kunbo Medical, and Advanced Medical
.
Among them, Xinwei Medical, sponsored by Goldman Sachs CICC, whose share price has been slashed since its listing
.
In addition, among the A-shares, the first day performance of Chengda Biotech, which was listed on October 28, was also surprising
.
As of the close of trading, the stock price has fallen by 27.
27%
.
In addition, according to incomplete statistics, after September this year, A shares also ushered in a wave of breaks
.
First, the listing applications of the two biomedical companies, Haihe Pharmaceutical and Jikai Gene, were rejected by the Securities Regulatory Commission before and after the listing, and then the number of companies accepted for listing on the Science and Technology Innovation Board has also changed significantly
.
Among them, the number of companies that accepted the Sci-tech Innovation Board in September was 13; in October, only 4 companies were accepted on the Sci-Tech Innovation Board, and there were no biomedical companies
.
The analysis believes that there are many reasons for the wave of break-ups, including the accelerated pace of new stock issuance, the recent lack of market sentiment, and the continuous high-priced issuance caused by the blind praise of "unbeaten new stocks" by all parties in the market
.
But in general, this type of break is not a bad thing.
The mature capital market itself has risen and fallen.
New stocks are the same as old stocks.
They should not necessarily go up just because they are new stocks.
.
At present, as the issuance of pharmaceutical stocks continues to break, the industry is expected to promote the rational return of new stock returns, and change IPO pricing from a game of behavior to a judgment on the true value of new stocks
.
It is worth mentioning that behind the successive breaks of the pharmaceutical stocks, some people in the industry have also pointed out that research capabilities are gradually replacing the finalist rate as the new distribution logic
.
Because on the whole, most of the products of companies that have fallen below the issue price have no real innovation
.
For example, the recently launched medical device companies such as Weitai Medical, Synred Medical, and Guichuang Tongqiao, whose main products are still around products such as embolization stents, drug balloons, insulin pumps, and interventional diagnosis and treatment
.
Although these products may have innovative technical points, there is no fundamental breakthrough in the treatment essence of products that have been circulating on the market for many years
.
What's more, these products are likely to face national centralized procurement in the future
.
In this context, the industry pointed out that as the market matures, future innovative drug companies are expected to be polarized after they go public: companies with innovative capabilities, R&D capabilities, and excellent products will be sought after by investors, and their stock prices will continue to rise; on the contrary, Companies with no innovation, backward R&D capabilities, and no distinctive features may experience issuance failure, breakage, low transaction volume (market value), or even delisting
.
